Raymond James analyst Jonathan Hughes upgraded Healthpeak Properties (DOC) to Outperform from Market Perform with a $20 price target The firm cites the stock’s recent underperformance relative to peers, driven by a large Q2 occupancy decline in the life science segment, and expectations for limited downside to life science fundamentals going forward for the upgrade. Healthpeak shares trade at an attractive valuation given its “well-covered” 6.7% dividend yield, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOC:
- Healthpeak Properties price target lowered to $21 from $22 at Morgan Stanley
- Deutsche downgrades Healthpeak to Hold on biotech challenges
- Healthpeak Properties downgraded to Hold from Buy at Deutsche Bank
- Ex-Dividend Date Nearing for These 10 Stocks – Week of August 18, 2025
- Healthpeak Properties Completes $500 Million Senior Notes Offering